Powered by

On October 28, biological drug and product manufacturer, Samsung BioLogics, successfully raised $2bn in what is the world’s largest healthcare sector IPO since Healthscope’s $2.1bn offering in 2014. The deal priced at the top of the range and is also South Korea’s largest IPO in 6 years.

As a trusted financial platform partner, Dealogic helped the bookrunners seamlessly execute the transaction through the DealManager network, who were also kept updated with real-time mobile access via Pulse.

Transaction Details

Issuer: Samsung BioLogics

Nationality: South Korea

Industry: Healthcare

Deal Value ($m): 1,969

Deal Type: IPO

Bookrunners: Korea Investment & Securities, Citi, NH Investment & Securities, JPMorgan, and Credit Suisse

Key Points

Top 3 global healthcare IPOs in 2016 YTD

  1. Samsung BioLogics, $2.0bn | South Korea | Oct 2016
  2. ConvaTec Group, $1.8bn | United Kingdom | Oct 2016
  3. China Resources Pharmaceutical Group, $1.8bn | Hong Kong | Oct 2016

Top 3 South Korean IPOs on record

  1. Samsung Life Insurance, $4.4bn | Insurance | Apr 2010
  2. Lotte Shopping, $3.7bn | Retail | Jan 2006
  3. Samsung BioLogics, $2.0bn | Healthcare | Oct 2016


For more information on why South Korea is Asia’s ECM bright spot, watch our video here.



More in ECM:

  1. Video

    Resurgence in Asian equity capital market offerings

    March 2017

  2. Video

    Snap: the first day pop and the outlook for US markets

    March 2017

  3. Infographic

    Snap raises $3.4bn in largest US tech IPO in 5 years

    March 2017

  4. Report

    Strongest start for US-listed IPOs in 3 years

    February 2017